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INTRODUCTION
Fluconazole is an azole antifungal agent active
against Candida spp. and Cryptococcus spp. It can
be administered orally or intravenously. It has
been used for treating Candida infections, and is
effective in treating infections caused by strains of
Candida albicans, Candida tropicalis and Candida
parapsilosis without acquired resistance mecha-
nisms. The drug is ineffective for treating infec-
tions caused by Candida krusei, which is naturally
resistant. The response of infections caused by
Candida glabrata is variable, as the wild-type MIC
distribution straddles most reasonable MIC
breakpoints. Every attempt should be made to
identify Candida isolates to the species level before
or in conjunction with antimicrobial susceptibility
testing.
The EUCAST-AFST (European Committee on
Antimicrobial Susceptibility Testing—Subcom-
mittee on Antifungal Susceptibility Testing)
has determined breakpoints of fluconazole for
Candida spp. This Technical Note is based on
the EUCAST fluconazole rationale document
(available on the EUCAST website: http://www.
eucast.org). The rationale document includes
more detail and published references related to
the selection of EUCAST-AFST breakpoints.
DOSAGE
The EUCAST-AFST has determined clinical break-
points for a fluconazole dose of 400–800 mg ⁄day,
given orally or parenterally.
MIC DISTRIBUTIONS
The MIC values for wild-type Candida spp. are
shown in Table 1. The MIC distributions are
based on large collections of MIC values from
several investigators, obtained using the
EUCAST-AFST, CLSI and Etest methods. Wild-
type isolates of C. albicans, C. tropicalis and
C. parapsilosis exhibit MICs of £2 mg ⁄L, whereas
MICs for C. glabrata are higher at 32 mg ⁄L, and
those for C. krusei are higher still at up to
128 mg ⁄L. Updates on wild-type MIC distribu-
tions can be found at http://www.eucast.org.
ESTABLISHED BREAKPOINTS
Only Norway and Germany have established
national breakpoints for fluconazole, at sensitive
(S) £4 ⁄ resistant (R) >32 mg ⁄L and S £4 ⁄R >16
mg ⁄L respectively.
PHARMACOKINETIC DATA
The pharmacokinetic data used to evaluate fluco-
nazole were based on standard doses of 400 and
800 mg (Table 2).
PHARMACODYNAMIC DATA
Fluconazole is thought to be fungistatic when
given in lower doses, and fungicidal when given
in higher doses. The pharmacodynamic index
best related to outcome is the fAUC ⁄MIC. This is
virtually the same as the dose ⁄MIC, since the
AUC and the dose are highly correlated. Hence,
dose provides a good surrogate for the AUC. The
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pharmacokinetic ⁄pharmacodynamic target was
explored using Monte Carlo simulations to
estimate the likelihood that a target fAUC ⁄MIC
of 50–100 could be attained. Most cases of cand-
idosis involve immunocompromised patients;
hence, fungicidal levels are considered to be a
prerequisite for success. Therefore, an fAUC ⁄MIC
target of at least 100 is desirable. Classification
and regression tree (CART) analysis supports this
target, since >90% of patients given at least
100 mg of fluconazole daily are likely to respond.
CLINICAL EFFICACY
There is an almost 1:1 linear relationship between
the AUC and the dose of fluconazole. There is also
a direct, albeit imperfect, relationship between the
AUC (or dose) and a successful clinical response
in cases of oral candidosis and, to a lesser extent,
in cases of candidaemia. Similarly, cure is less
likely for infections caused by strains with higher
MICs.
The EUCAST-AFST considers that fluconazole
is appropriate therapy for candidaemia in neu-
tropenic and non-neutropenic patients, chronic
disseminated candidosis, disseminated cutaneous
neonatal candidosis, urinary tract infections, lower
respiratory tract infections, osteomyelitis,
arthritis, infections of the gallbladder, pancreas
and peritoneum, endocarditis, pericarditis, sup-
purative phlebitis, myocarditis, meningitis and
endophthalmitis caused by Candida spp., non-
genital mucocutaneous candidosis and genital
candidosis.
The EUCAST-AFST considers that fluconazole
is appropriate prophylaxis for neutropenic
patients, particularly those colonised with C. trop-
icalis, as well as for allogeneic haematopoietic
stem-cell transplant recipients and recipients of
liver transplants, who are considered to be at high
risk for infection.
BREAKPOINTS
Breakpoints are summarised in Table 3.
Non-species-related breakpoints
These have been determined mainly on the basis
of pharmacokinetic ⁄pharmacodynamic data, and
are independent of the MIC distributions for
specific species. The column ‘non-species-related
breakpoints’ is reserved for those species not
indicated separately in Table 3. These breakpoints
Table 1. Fluconazole MIC distributionsa for Candida spp.
Species
ECOFF
(mg ⁄L)0.016 0.032 0.064 0.125 0.25 0.5 1 2 4 8 16 32 64 128 256 512
Candida albicans 14 57 275 4010 6737 2518 1081 439 136 154 107 88 247 92 35 1 1
Candida glabrata 2 7 5 14 11 48 110 323 888 1204 1353 534 261 157 75 26 32
Candida krusei 0 0 0 0 0 0 0 0 1 9 50 314 229 59 11 0 128
Candida parapsilosis 0 0 4 62 415 980 646 241 70 58 39 11 5 2 2 1 2
Candida tropicalis 0 0 2 119 443 743 513 269 60 24 27 10 9 10 0 0 2
ECOFF, epidemiological cut-off value (mg ⁄L) as defined by EUCAST.
aMICs determined according to EUCAST, CLSI and Etest methods are included in the distributions. Separate distributions for the three methods are shown on http://
www.eucast.org.
Table 2. Pharmacokinetic data for fluconazole
Parameter
Dosage (mg) 400 800
Cmax (mg ⁄L) 18.9–30.6 34
Cmin (mg ⁄L) 21–23 NA
Total body clearance (L ⁄h) NA NA
T1 ⁄ 2 (h) 31–37.2 31–37.2
AUC24 h (mg.h ⁄L) 350 813.27
Fraction unbound (%) 88–89 88–89
Volume of distribution (L) 0.7–0.8 0.7–0.8
NA, not available.
Table 3. EUCAST clinical MIC breakpoints for fluconazole, 17 April 2007
Species-related breakpoints (S£ ⁄R>)
Non-species-related
breakpoints (S£ ⁄R>)Candida albicans Candida tropicalis Candida parapsilosis Candida glabrata Candida krusei
Fluconazole 2 ⁄ 4 2 ⁄ 4 2 ⁄ 4 IE – 2 ⁄ 4
IE, there is insufficient evidence that the species in question is a good target for therapy with fluconazole; –, susceptibility testing not recommended, as this species is a poor
target for therapy with fluconazole.
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should not be applied to species for which
susceptibility testing is not recommended
(marked with ‘–’ or ‘IE’ in EUCAST breakpoint
tables).
Species-related breakpoints
The in-vitro activity of fluconazole against Candida
spp. is not uniform. The species associated most
frequently with human infections include C. albi-
cans, C. parapsilosis and C. tropicalis, and these
exhibit MIC values of £2 mg ⁄L when mechanisms
of resistance to fluconazole are absent.
Species without breakpoints
C. krusei is considered to be inherently resistant,
exhibiting high MIC values. A significant number
of infections involve C. glabrata, which exhibits
fluconazole MICs of 2–32 mg ⁄L. Any reasonable
breakpoint would divide wild-type C. glabrata
isolates, thereby frustrating reliable and repro-
ducible susceptibility testing. For these reasons,
the EUCAST-AFST has refrained from assigning
breakpoints for fluconazole to C. krusei and
C. glabrata, and advises that alternative drugs be
employed to manage infections caused by these
species. One exception would be urinary tract
infections caused by C. glabrata, since fluconazole
is concentrated in the urine to levels that are likely
to exceed the MIC for this species. This fact also
serves to emphasise the need to correctly identify
yeast isolates recovered from urine and other
clinical specimens.
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